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Abstract
Background:  Severe alpha1-antitrypsin (AAT) deficiency associated with low AAT blood
concentrations is an established genetic COPD risk factor. Less is known about the respiratory
health impact of variation in AAT serum concentrations in the general population. We cross-
sectionally investigated correlates of circulating AAT concentrations and its association with FEV1.
Methods: In 5187 adults (2669 females) with high-sensitive c-reactive protein (CRP) levels ≤ 10
mg/l from the population-based Swiss SAPALDIA cohort, blood was collected at the time of follow-
up examination for measuring serum AAT and CRP.
Results:  Female gender, hormone intake, systolic blood pressure, age in men and in
postmenopausal women, as well as active and passive smoking were positively, whereas alcohol
intake and BMI inversely correlated with serum AAT levels, independent of CRP adjustment. We
observed an inverse association of AAT with FEV1 in the total study population (p < 0.001), that
disappeared after adjustment for CRP (p = 0.28). In addition, the AAT and FEV1 association was
modified by gender, menopausal status in women, and smoking.
Conclusion:  The results of this population-based study reflect a complex interrelationship
between tobacco exposure, gender related factors, circulating AAT, systemic inflammatory status
and lung function.
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Introduction
Alpha1-antitrypsin (AAT), a polymorphic inflammation-
sensitive plasma protein with antiprotease activity, pro-
tects the lung tissue from destruction by neutrophil
elastase. Severe and intermediate AAT deficiency is one of
the most common inherited diseases on a global scale [1].
It increases the risk of chronic obstructive pulmonary dis-
eases (COPD) in active smokers [2,3]. The two most com-
mon deficiency alleles are the S- and Z-allele, but at least
30 rare, additional alleles exist that are associated with
reduced or absent plasma AAT levels [4].
International AAT deficiency registries have advanced the
epidemiologic understanding of genetically determined
AAT deficiency. Much less is known about the respiratory
health impact of variation in AAT serum concentrations as
observed in the general population. According to a study
in healthy blood donors only 26% of the variance in cir-
culating AAT was explained by known AAT gene variants
[5]. In a population-based sample of school children pul-
monary function was positively associated with C-reactive
protein (CRP)-adjusted AAT levels, independent of PI
phenotypes [6]. In contrast, an inverse association
between inflammation-sensitive proteins, including non-
CRP adjusted serum AAT, and pulmonary function has
been described in population-based samples of adults
[7,8]. These reported opposite directions of the lung func-
tion/AAT association may in part be due to differences in
adjustment for CRP between the studies. They also agree
with the dual role of AAT as both, an antiprotease and an
inflammatory marker. Low-grade systemic inflammation
is increasingly being recognized as a COPD risk factor [9].
In the population-based Swiss Cohort Study of Air Pollu-
tion and Lung Disease in Adults (SAPALDIA) we investi-
gated the potential value of circulating AAT as a biomarker
for susceptibility to respiratory disease in the general pop-
ulation. First, we identified environmental and lifestyle
factors associated with AAT concentrations in the blood.
Second, we investigated the cross-sectional association
between circulating AAT concentrations and forced expir-
atory volume in one second (FEV1).
Methods
Study population
The SAPALDIA cohort has been described [10,11]. At
baseline in 1991 the SAPALDIA participants were aged
18–60 years. They are predominantly of European-Cauca-
sian ethnicity and Swiss nationality. They were randomly
selected from eight population registries representing the
three major Swiss language regions and including both,
urban and rural areas. Health examinations at baseline
and after 11-years included an interview about respiratory
health, occupational and lifestyle exposures as well as
spirometry. Participation rate at baseline was 59.3%. The
current, cross-sectional investigation of AAT is restricted to
follow-up data collected in 2002/2003 when the blood
bank was established (Figure 1 and Table 1 for more
detail). Ethical approval for the study was given by the
central ethics committee of the Swiss Academy of Medical
Sciences and the Cantonal Ethics Committees for each of
the eight examination areas.
Measurements
Lung function
Lung function was assessed using spirometry (Sensormed-
ics model 2200, Yorba Linda, USA) according to ATS cri-
teria The present analysis focused on FEV1 expressed as %
predicted, derived from SAPALDIA-specific prediction
equation [12].
Tobacco exposure, alcohol intake and female hormone-related 
variables
Information about active and passive smoking was col-
lected by an extended version of the European Commu-
Participation in SAPALDIA baseline and follow-up examina- tion and in the current cross-sectional study Figure 1
Participation in SAPALDIA baseline and follow-up 
examination and in the current cross-sectional study. 
The current, cross-sectional investigation of AAT is 
restricted to data collected in 2002/2003 when the blood 
bank was established. The analysis of factors correlated with 
serum AAT levels (Tables 2 and 7) is restricted to 5187 fol-
low-up participants (*), whereas the association between 
serum AAT and FEV1 was further restricted to 4449 follow-
up participants with valid lung function measurements (**) 
(Tables 4, 5 and 6).
Participation in SAPALDIA 1 at baseline:
9651 participants with interview questionnaire data
- 8881 with complete lung volume data
283 died
653 moved abroad or address untraceable
668 refused
Participation in SAPALDIA 2 at follow-up:
8047 participants at follow-up (participation in any module):
- 7673 participants in interview *
- 6218 participants in interview and spirometry**
Participants for determinants of AAT *
- 6317 gave blood;valid AAT/ CRP measurements;CRP10mg/l
- 5187 with complete data on all co-variates 
Participants for association of AAT with lung function **
- 5356 gave blood; valid AAT/CRP measurements;CRP10mg/l
- 4449 with complete data on all co-variatesRespiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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nity Respiratory Health Survey (ECRHS) questionnaire
[13]. Smoking was categorized as current (smoking within
month before interview), former, and never smoking at
follow-up. Never and former smokers were classified as
environmental tobacco smoke (ETS) exposed based on an
affirmative answer to a question about regular exposure to
ETS in the 12 months before the interview. Smoking
intensity was calculated as total pack years smoked ([years
of smoking * mean cigarettes/day]/20). Current smokers
were a priori divided into two subgroups: <15 cigarettes/
day vs. ≥ 15 cigarettes/day. Alcohol consumption was a
priori classified as daily versus not daily drinking (≥1 vs.
<1 alcoholic drink per day).
Women were categorized as pre- and postmenopausal.
Women whose menses had become less regular within 12
month before the interview were defined as perimeno-
pausal. Current exogenous hormonal intake was assessed
by the questions "have you ever taken oral contraceptives
(OC) or hormone replacement therapy (HRT)?", and
"were you still taking OC or HRT during the last month
before the interview?"
Physical examination
Mean values of 2 automatic measurements of systemic
blood pressure (BP) (OMRON 705 CP, Tokyo, Japan)
were used and pulse pressure (PP) – a measure of artery
stiffness – was calculated as the difference between systo-
lic and diastolic BP [14]. Weight and height were meas-
ured by electronic (TERRAILLON, Bradford, MA, USA),
and telescopic scales (SECA, Hamburg, Germany), respec-
tively for the assessment of body mass index (kg/m2;
BMI).
Serum analysis
AAT (g/l) and high-sensitivity c-reactive protein (CRP)
(mg/l) concentrations were determined by latex-
enhanced immunoturbidimetric assays (Roche Diagnos-
tics, Mannheim, Germany on a Roche COBAS INTEGRA
analyzer, Rotkreuz, Switzerland) with interassay coeffi-
cients of variation below 5%. Lower detection rates for the
AAT and CRP assays were 0.21 g/l, and 0.1 mg/l, respec-
tively.
Statistical analysis and sample size
All statistical analyses were restricted to subjects without
signs of an acute infection (CRP ≤ 10 mg/l).
First, we identified the independent association of gender,
age, BMI, smoking status, packyears, ETS exposure, and
alcohol consumption with AAT concentrations among
5187 participants. Analysis of covariance with and with-
out CRP adjustment was performed to estimate adjusted
mean (SE) AAT serum concentrations (g/l).
Second, we investigated the association between circulat-
ing AAT and FEV1% predicted. Given the correlations of
CRP with both, AAT (Table 2) and FEV1 (Table 3), we
investigated the association with and without CPR-adjust-
ment. The regression models included sex, study area,
systolic blood pressure, body mass index (BMI), smoking
status (never, former, current), alcohol consumption, ETS
(never and former smokers), pack years smoked (current
smokers), time since quitting (former smokers), cigarettes
smoked/day (current smokers), menopausal status and
hormone intake (women) as covariates. Analysis of covar-
iance was performed to estimate adjusted mean FEV1%
predicted values (standard errors) for AAT quintile classes.
To evaluate dose-response relationships, predictor varia-
bles were categorized into suitable quantile classes, and
regression models without the respective predictor varia-
bles were computed. A Cuzick's trend test [15] was then
used to test whether regression residuals showed a monot-
onous association with increasing levels of the predictor
in question. Effect modification was assessed by including
interaction terms between AAT as a continuous variable
and the potential effect modifier of interest in the models.
Interactions with a p-value < 0.05 were considered statis-
tically significant [16]. In the absence of information on
SERPINA1 genotype variants and to avoid unrecognized
confounding or effect modification by unrecognized
severe and intermediate AAT deficiency genotypes, the
Table 1: Characteristics at the baseline examination of participants in different parts of the study
SAPALDIA baseline participants SAPALDIA participants in study on AAT 
determinants
SAPALDIA participants in study on AAT 
and lung function
N 9651 5187 4449
Female, % 50.7 51.5 48.6
Age (mean, SD) [years] 41.7 (11.7) 40.9 (11.5) 41.1 (11.4)
BMI (mean, SD) [kg/m2] 24.0 (3.9) 23.6 (3.5) 23.7 (3.5)
Smoking Status, %
- never 43.9 49.8 47.8
- former 22.6 20.6 22.0
- current 33.5 29.6 30.2
FEV1 (mean, SD) [ml/s] 3.53 (0.85) 3.59 (0.83)Respiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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main multiple linear regressions were restricted to partic-
ipants exhibiting normal serum AAT concentrations (≥ 0.9
g/l; indicating the normal cut-off value for AAT serum
concentrations according to the consensus reference data
[CRM470/RPPHS] [17]). The main FEV1 analyses there-
fore included 4297 subjects (never smokers = 2028,
former smokers = 1336, current smokers = 933) with com-
plete data on lung function and covariates. Nevertheless
and despite limited sample size, predicted means for the
small category of subjects with serum AAT < 0.90 g/l (Q0:
Table 2: Adjusted* mean AAT serum levels by age, gender, anthropometrics, blood pressure, crp, and lifestyle variables (n = 5187)
Number of subjects AAT (SE) (g/L), no CRP 
adjustment
AAT (SE) (g/L), CRP 
adjustment
Gender Men 2518 1.203 (0.004) 1.215 (0.004)
Women 2669 1.305 (0.004) 1.293 (0.004)
p < 0.001 p < 0.001
Age Quartiles (years):
Men <43 630 1.194 (0.007) 1.195 (0.007)
<53 629 1.200 (0.007) 1.205 (0.006)
<61 630 1.208 (0.007) 1.208 (0.006)
<73 629 1.239 (0.007) 1.233 (0.007)
p trend < 0.001 p trend = 0.001
Premenopausal women¶,† <38 202 1.314 (0.013) 1.312 (0.012)
<43 201 1.284 (0.013) 1.284 (0.012)
<50 202 1.278 (0.013) 1.281 (0.012)
<55 201 1.227 (0.013) 1.227 (0.012)
p trend < 0.001 p trend < 0.001
Postmenopausal women¶,† <55 212 1.221 (0.014) 1.221 (0.013)
<61 212 1.255 (0.013) 1.261 (0.012)
<67 212 1.281 (0.013) 1.276 (0.013)
<73 212 1.275 (0.013) 1.273 (0.013)
p trend 0.05 p trend 0.07
BMI Quartiles (kg/m2):
<22.79 1338 1.284 (0.005) 1.306 (0.005)
<25.38 1349 1.250 (0.005) 1.257 (0.005)
<28.36 1287 1.241 (0.005) 1.237 (0.005)
≥28.36 1213 1.247 (0.005) 1.218 (0.005)
p trend = 0.003 p trend < 0.001
Systolic blood pressure Quartiles (mmHg):
<114 1342 1.240 (0.006) 1.244 (0.005)
<126 1279 1.252 (0.005) 1.254 (0.005)
<139 1304 1.260 (0.005) 1.259 (0.005)
≥139 1262 1.272 (0.006) 1.266 (0.005)
p trend < 0.001 p trend 0.002
Tobacco exposure‡ Never smokers/ETS- 2121 1.236 (0.005) 1.238 (0.004)
Never smokers/ETS+ 388 1.260 (0.010) 1.269 (0.009)
Former smokers/ETS- 1188 1.238 (0.006) 1.240 (0.005)
Former smokers/ETS+ 312 1.249 (0.011) 1.249 (0.010)
Current smokers, <15 cig/d) 515 1.284 (0.008) 1.285 (0.008)
Current smokers, ≥15 cig/d) 662 1.328 (0.009) 1.314 (0.008)
p trend < 0.0001 p trend < 0.0001
Alcohol intake <1 drink per day 4069 1.261 (0.003) 1.262 (0.003)
≥1 drink per day 1118 1.235 (0.006) 1.234 (0.007)
p < 0.001 p < 0.001
CRP Quartiles (mg/l):
<0.6 1506 1.182 -
<1.1 1202 1.227 -
<2.2 1232 1.268 -
≥ 2.2 1247 1.360 -
P trend < 0.00001
*adjusted for age, gender, smoking status, alcohol intake, BMI, systolic blood pressure and study area ¶women taking oral contraceptives (n = 166), 
hormone replacement (n = 524), with perimenopausal status (n = 82), and unclear/missing hormonal status (n = 243) were excluded; †p(interaction) 
pre-versus postmenopausal women <0.001; ‡ n = 5186, due to 1 former smoker with missing ETS exposure; ETS = environmental tobacco 
exposureRespiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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n = 152) are also presented in Tables 4, 5 and 6. STATA
software, release 8.2 (StataCorp, TX, USA) was used for all
statistical analyses.
Results
At baseline 9651 subjects were recruited into the SAPAL-
DIA cohort, of whom 8881 underwent lung function test-
ing (Figure 1). Of the 7673 participants in the interview at
follow-up (Fig.1, see *), 5187 were included in the analy-
sis of factors associated with serum AAT (Table 2 and 7).
Equivalently, of the 6218 participants in both, interview
and spirometry at follow-up (Fig. 1, see **), 4449 were
included in the analysis of the serum AAT/FEV1% pre-
dicted association (Tables 4, 5 and 6). A comparison of
baseline characteristics between all SAPALDIA partici-
pants (n = 9651) and subjects included in the two current
sub-studies (AAT determinants (n = 5187); AAT/FEV1%
predicted (n = 4449) is listed in Table 1. As previously
described in detail, never smokers were overrepresented
among participants at follow-up and thus in the two
cross-sectional sub-studies [11].
AAT serum levels: association with age, gender, 
anthropometrics, blood pressure, lifestyle, and hormonal 
variables
At the follow-up examination, mean (SD) age in men (n
= 2518) and women (n = 2669) included in the investiga-
tion of AAT determinants was 51 [12] and 52 [11] years,
respectively, and mean BMI 26.45 (3.72) and 24.96
(4.55) kg/m2, respectively. In both gender groups com-
bined, 23% reported current and 29% reported former
smoking at follow up. Mean (SD) pack years smoked in
current and former smokers was 30 [23] and 21 [23] pack
years, respectively. Two thousand five hundred and nine
subjects had never smoked actively (59% females), of
whom 15% were exposed to environmental tobacco
smoke (ETS) within 12 months before the follow-up
interview. Among these, 137 (35%) were exposed to ETS
more than 3 hours per day. Among the premenopausal
women, 166 (21%) reported oral intake of contraceptives,
and hormone replacement therapy was reported by 524
(61%) of the postmenopausal women. Serum AAT con-
centrations ranged from 0.38 to 2.24 g/l with a mean (SD)
of 1.26 (0.20) g/l. One hundred and seventy eight subjects
(3.4%) had a serum AAT level below 0.9 g/l, the recom-
mended test limit for further clinical and laboratory inves-
tigation of genetic AAT deficiency [17].
The associations of age, gender, anthropometric parame-
ters, blood pressure, lifestyle and hormonal variables with
serum AAT are shown in Tables 2 and 7. Women had
higher circulating AAT concentrations (p < 0.001) (Table
2).
The AAT/age association differed by gender and meno-
pausal status in women (p interaction <0.001 for both).
In men and postmenopausal women age was positively
associated with AAT whereas an inverse association was
present in premenopausal women. None of the remaining
AAT predictors was modified by gender. Systolic blood
pressure and pulse pressure (data not shown) were posi-
tively associated with serum AAT (p trend = 0.002 and
<0.001, respectively), BMI and regular alcohol consump-
tion inversely. Serum AAT increased with tobacco smoke
exposure in a dose-dependent fashion. ETS-exposed never
smokers had higher AAT serum levels than non-exposed
never smokers. Serum AAT was highest in active smokers
consuming at least 15 cigarettes per day (p linear trend <
0.001).
In women, we assessed the association of menopausal sta-
tus and intake of female hormones (oral contraceptives or
hormone replacement therapy) with serum AAT (Table 7).
Among women without intake of female hormones,
serum AAT was higher in premenopausal women (p =
0.003). Use of oral contraceptives (premenopausal) and
of hormone replacement therapy (postmenopausal) was
associated with elevated AAT concentrations in the blood
(p < 0.001 for both).
The associations of serum AAT with the factors listed in
Tables 2 and 7 were insensitive to CRP adjustment. CRP
Table 3: Association (z-value; p trend) of FEV1 %predicted with 
CRP quartile classes§
z-value# ptrend (across crp quartiles)
Non-smoking men
FEV1 (% predicted)* -3.91 <0.000
FEV1 (% predicted)** -4.53 <0.000
Non-smoking women ¶
FEV1 (% predicted)* -2.32 0.02
FEV1 (% predicted)** -2.15 0.03
Smoking men
FEV1 (% predicted)* -2.44 0.015
FEV1 (% predicted)** -4.82 <0.000
Smoking women ¶
FEV1 (% predicted)* -2.44 0.015
FEV1 (% predicted)** -3.14 0.002
*controlled for BMI, systolic blood pressure, ETS (in non smokers), 
packyears (in smokers), alcohol intake, study area; ** crude 
associations; ¶additionally adjusted for menopausal status, and intake 
of female hormones; subjects with crp > 10 mg/l were excluded; 
§CRP quartiles (Q) (mg/l): Q1 < 0.6, Q2 < 1.1, Q3 < 2.2, Q4 > 2.2; # 
Regression models without CRP quartiles as predictor variable were 
computed first. A Cuzick's trend test was then used to test whether 
regression residuals showed a monotonous association with CRP 
quartiles. Under the null hypothesis of no trend, the z-value of 
Cuzick's trend test statistic approximately follows a standard normal 
distribution, enabling the computation of approximate p-values; a 
negative sign indicates an inverse association between CRP and 
FEV1%predicted [15].Respiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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itself was positively associated with AAT (Table 2). Results
in Tables 2 and 7 were insensitive to the exclusion of sub-
jects with AAT levels below 0.9 g/l or below 1.04 g/l (0.9
g/l: normal cut-off for serum AAT [17]; 1.04 g/l: lower 10th
percentile of the AAT distribution in this study).
AAT serum levels: association with lung function
In the total study population, AAT was inversely associ-
ated with FEV1, but only in the absence of CRP adjust-
ment (Table 4).
The inverse association was restricted to men (not CRP
adjusted p interaction AAT*gender = 0.007). The AAT/FEV1
association was also modified by smoking. An inverse
association before CRP adjustment was observed in never/
former smokers (p < 0.001) and in current smokers con-
suming 15 cigarettes or less per day. In contrast, CRP
adjusted AAT and FEV1 were positively correlated in heavy
current smokers (p = 0.01) (not CRP adjusted p interac-
tion  AAT*(current smokers >= 15 cigs/day vs. all others): = 0.14 in all
subjects; = 0.03 in men; = 0.11 in women).
Results on the AAT/FEV1 association stratified by both,
gender and smoking, are presented in Tables 5 and 6. As
we observed a statistically significant interaction between
menopausal status and AAT in all women, irrespective of
smoking status and CRP adjustment (not CRP adjusted p
interaction AAT*menopausalstatus = 0.008), analyses in women
were further stratified by menopausal status.
Among participants not currently smoking, FEV1 was
inversely related to AAT in both, men and postmenopau-
sal women, irrespective of CRP adjustment (Table 5).
Table 4: Mean (SE) FEV1 %predicted in relation to AAT quintile classes †
Quintile classes of AAT (g/l)
Q0 (<0.9) Q1 (≥0.9–
<1.13)
Q2 (≥1.13, 
<1.22)
Q3 (≥1.22, 
<1.31)
Q4 (≥1.31, 
<1.41)
Q5 
(≥1.41)
ptrend from model 
not including Q0
All (n) ¶ 152 952 832 932 764 817
FEV1 (% predicted) CRP adj. 99.8 (1.2) 98.0 (0.5) 98.3 (0.5) 98.1 (0.5) 97.6 (0.5) 96.6 (0.5) 0.28
FEV1 (% predicted), no CRP adj. * 100.4 (1.2) 98.7 (0.5) 98.7 (0.5) 98.2 (0.5) 97.4 (0.5) 95.5 (0.5) <0.001
Men (n)‡ 79 627 511 460 351 256
FEV1 (% predicted) CRP adj. 99.0 (1.6) 96.7 (0.6) 97.3 (0.6) 97.2 (0.6) 95.8 (0.8) 93.8 (1.0) 0.08
FEV1 (% predicted), no CRP adj. * 99.3 (1.6) 97.3 (0.6) 97.6 (0.6) 97.1 (0.7) 95.4 (0.8) 92.6 (0.9) <0.001
Women (n) ¶, ‡ 73 325 321 472 413 561
FEV1 (% predicted) CRP adj. 100.6 (1.6) 99.4 (0.8) 99.2(0.8) 99.3(0.7) 99.2 (0.7) 98.8 (0.6) 0.76
FEV1 (% predicted), no CRP adj. * 101.4 (1.7) 99.9 (0.8) 99.7(0.8) 99.5(0.7) 99.3 (0.7) 97.8 (0.6) 0.19
Never/Former Smokers (n) ¶, ‡ 130 811 721 754 541 537
FEV1 (% predicted), CRP adj. 100.4 (1.3) 99.1 (0.5) 99.0 (0.5) 99.1 (0.5) 98.4 (0.6) 96.9 (0.7) 0.10
FEV1 (% predicted), no CRP adj.* 100.9 (1.3) 99.6 (0.5) 99.3 (0.5) 99.1 (0.5) 98.2 (0.6) 95.9 (0.7) <0.001
Current Smokers (n) ¶, ‡ 22 141 111 178 223 280
FEV1 (% predicted), CRP adj. 96.9 (2.9) 93.6 (1.2) 95.0 (1.3) 93.8 (1.0) 94.5 (0.9) 95.6 (0.9) 0.16
FEV1 (% predicted), no CRP adj.* 97.2 (2.9) 94.3 (1.0) 95.7 (1.3) 94.3 (1.0) 94.7 (0.9) 94.5 (0.9) 0.91
Currents Smokers ≥15 cigs/d (n) ¶,‡ 11 60 48 103 122 182
FEV1 (% predicted), CRP adj. 96.5 (4.3) 88.8 (1.9) 93.6 (2.1) 91.2 (1.4) 93.6 (1.3) 95.3 (1.1) 0.01
FEV1 (% predicted), no CRP adj.* 96.7 (4.3) 89.7 (1.9) 94.4 (1.1) 91.2 (1.4) 93.9 (1.3) 94.4 (1.1) 0.06
Currents Smokers <15 cigs/d (n) ¶,‡ 11 81 63 75 101 98
FEV1 (% predicted), CRP adj. 99.6 (3.9) 98.3 (1.5) 96.9 (1.7) 96.6 (1.5) 95.8 (1.3) 94.9 (1.5) 0.21
FEV1 (% predicted), no CRP adj.* 99.9 (3.9) 98.9 (1.5) 97.6 (1.4) 97.2 (1.5) 95.9 (1.3) 93.5 (1.4) 0.02
† adjusted for gender, smoking status (never, former, current), years since quitting in former smokers, cigarettes/day in current smokers, passive 
smoking in never smokers, BMI, systolic blood pressure, alcohol consumption, study area, menopausal status in women, intake of female hormones 
in women, CRP, CRP2 (models with CRP adjustment); * adjusted for all covariates but CRP; ¶women in perimenopausal status (n = 35) and missing/
unclear status and hormonal intake (n = 120) were excluded from the analysis; ‡ P-values for interactions: In All: AAT*gender: p = 0.02(CRP adj); p 
= 0.007(no CRP adj.); In women: AAT*menopausal status: 0.01 (CRP adj.); 0.008 no CRP adj.); AAT*intake female hormones: p > 0.80, irrespective 
of menopausal status; AAT*smoking (heavy current smoking vs. all others): all men: p = 0.02 (CRP adj.); p = 0.03 (no CRP adj.); all women: p = 0.11 
(CRP adj.); p = 0.11 (no CRP adj.); postmenopausal women: p = 0.08 (CRP adj.); p = 0.07 (no CRP adj.); premenopausal women: p = 0.59 (CRP adj.); 
p = 0.58 (no CRP adj.)Respiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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Table 6: Mean (SE) FEV1 %predicted in relation to AAT quintile classes in current smokers †
Quintile classes of AAT (g/l)
Q0 (≤ 0.9) Q1 (≥0.9–
<1.13)
Q2 (≥1.13, 
<1.22)
Q3 (≥1.22, 
<1.31)
Q4 (≥1.31, 
<1.41)
Q5 (≥1.41) ptrend from model 
not including Q0
Men (n) 13 105 72 109 125 114
FEV1 (% predicted), CRP adj.† 95.1 (3.8) 92.8 1.4) 93.8 (1.7) 93.4 (1.3) 93.2 (1.2) 95.4 (1.4) 0.30
FEV1 (% predicted), no CRP adj.* 95.6 (3.8) 93.3 (1.4) 94.1 (1.7) 93.8 (1.3) 93.3 (1.2) 94.3 (1.3) 0.71
Men ≥15 cigs/day (n) 6 47 33 72 72 87
FEV1 (% predicted), CRP adj.† 95.3 (5.7) 89.3 (2.1) 93.3 (2.5) 91.2 (1.7) 93.7 (1.6) 95.5 (1.6) 0.04
FEV1 (% predicted), no CRP adj.* 89.7 (2.1) 89.7 (2.1) 93.3 (2.5) 91.4 (1.7) 93.8 (1.7) 94.9 (1.6) 0.07
Men <15 cigs/day (n) 7 58 39 37 53 27
FEV1 (% predicted), CRP adj.† 96.5 (5.0) 96.0 (1.8) 94.3 (2.2) 96.6 (2.2) 92.99 (1.9) 94.1 (2.8) 0.38
FEV1 (% predicted), no CRP adj.* 97.3 (2.2) 96.7 (1.7) 95.2 (2.2) 97.0 (2.2) 92.5 (1.9) 91.1 (2.6) 0.05
Women (n) ¶ 9 36 39 69 98 166
FEV1 (% predicted), CRP adj.† 98.6 (4.5) 94.6 (2.3) 96.8 (2.2) 94.1 (1.6) 95.9 (1.3) 96.7 (1.1) 0.24
FEV1 (% predicted), no CRP adj.* 98.6 (4.5) 95.5 (2.3) 92.2 (2.2) 94.9 (1.6) 96.4 (1.4) 95.5 (1.1) 0.99
Premenopausal (n) 4 21 21 32 40 81
FEV1 (% predicted), CRP adj.† 98.8 (6.2) 96.1 (2.7) 95.4 (2.7) 97.0 (2.2) 100.2 (2.0) 94.6 (1.4) 0.71
FEV1 (% predicted), no CRP adj.* 98.8 (6.2) 96.7 (2.7) 95.3 (2.2) 99.0 (1.9) 101.0 (1.9) 93.6 (1.4) 0.64
Postmenopausal (n) 5 15 18 37 58 85
FEV1 (% predicted), CRP adj.† 98.3 (6.4) 91.7 (3.7) 97.7 (3.4) 92.4 (2.3) 92.3 (1.8) 99.2 (1.6) 0.15
FEV1 (% predicted), no CRP adj.* 97.1 (6.6) 93.7 (3.7) 99.6 (3.4) 93.5 (2.4) 92.7 (1.9) 97.7 (1.6) 0.69
Postmenopausal, ≥ 15 cigs/day 
(n))¶
4 8 7 19 31 53
FEV1 (% predicted), CRP adj.† 94.6 (8.3) 84.7 (5.5) 90.0 (6.0) 87.9 (3.6) 90.0 (2.7) 96.3 (2.2) 0.05
FEV1 (% predicted), no CRP adj.* 93.9 (8.5) 87.4 (2.2) 92.7 (6.2) 88.1 (3.7) 90.4 (2.9) 95.1 (2.2) 0.22
Postmenopausal, <15 cigs/day (n)¶ 1 7 1 11 82 73 2
FEV1 (% predicted), CRP adj.† 105.4 (12.3) 100.2 (4.6) 103.6 (3.8) 98.4 (3.0) 96.2 (2.3) 102.3 (2.4) 0.85
FEV1 (% predicted), no CRP adj.* 108.8 (12.6) 100.2 (4.7) 103.5 (3.8) 99.1 (3.0) 96.7 (2.3) 101.3 (2.2) 0.93
Table 5: Mean (SE) FEV1 %predicted in relation to AAT quintile classes in non-current smokers†
Quintile classes of AAT (g/l)
Q0 (<0.9) Q1 (≥0.9–
<1.13)
Q2 (≥1.13, 
<1.22)
Q3 (≥1.22, 
<1.31)
Q4 (≥1.31, 
<1.41)
Q5 (≥1.41) ptrend from model 
not including Q0
Men (n) 66 522 439 351 226 142
FEV1 (% predicted), CRP adj. 99.5 (1.8) 97.6 (0.6) 97.9 (0.7) 98.2 (0.8) 97.0 (1.0) 92.9 (1.3) 0.05
FEV1 (% predicted), no CRP adj.* 99.8 (1.8) 98.1 (0.6) 98.1 (0.6) 98.0 (0.8) 96.5 (0.9) 91.9 (1.2) <0.001
Women (n) ¶ 64 289 282 403 315 395
FEV1 (% predicted) CRP adj. 101.0 (1.8) 100.4 (0.9) 99.8 (0.9) 100.3 (0.7) 99.9 (0.8) 99.3 (0.8) 0.85
FEV1 (% predicted), no CRP adj. * 101.8 (1.8) 100.9 (0.9) 100.3 (0.9) 100.4 (0.7) 100.0 (0.8) 98.4 (0.7) 0.13
Premenopausal women (n) ¶ 27 100 109 151 131 187
FEV1 (% predicted), CRP adj. 98.7 (2.4) 98.3 (1.3) 97.2 (1.2) 99.6 (1.0) 101.5 (1.1) 99.7 (1.0) 0.02
FEV1 (% predicted), no CRP adj.* 99.1 (2.4) 98.8 (1.3) 97.1 (1.0) 99.6 (1.0) 101.7 (1.1) 99.1 (1.0) 0.11
Postmenopausal women (n) ¶ 37 189 173 252 184 208
FEV1 (% predicted), CRP adj. 102.5 (2.5) 101.5 (1.1) 101.5 (1.2) 100.8 (1.0) 98.8 (1.1) 98.7 (1.1) 0.04
FEV1 (% predicted), no CRP adj.* 103.4 (2.5) 102.1 (1.1) 101.7 (1.1) 101.0 (1.0) 98.7 (1.1) 97.7 (1.1) <0.001
† adjusted for BMI, passive smoking, years since quitting, systolic blood pressure, alcohol consumption, study area, CRP, CRP2 (models with CRP); 
* adjusted for all covariates but CRP; ¶additionally adjusted for menopausal status, intake of female hormones; women in perimenopausal status (n 
= 35) and missing/unclear status and hormonal intake (n = 120) were excluded;Respiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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In contrast, premenopausal non-smoking women exhib-
ited a positive correlation between FEV1 and CRP-
adjusted serum AAT (p = 0.02).
No inverse associations between FEV1 and AAT were
observed in current smokers upon stratification by gender
(Table 6).
Upon stratification by smoking intensity (< vs. ≥ 15 cigs/
day) the association between AAT and lung function
became positive in the group of heavy smokers after
adjustment for CRP in both, men and postmenopausal
women (men: p = 0.04; women: p = 0.05). Unfortunately,
we had insufficient power to stratify analysis in premeno-
pausal women by smoking intensity.
Analyses of the AAT/FEV1 associations were also repeated
by increasing the exclusion cutoff to AAT levels below
1.04 g/l (lower 10th percentile of the AAT distribution in
this study). The results presented in Tables 4, 5 and 6 were
insensitive to this additional exclusion. It is notable that
subjects with AAT < 0.9 g/l generally exhibited good lung
function (Tables 4, 5 and 6), although data in this cate-
gory was sparse.
Discussion
The main and general message of the present paper is that
circulating AAT was inversely correlated with FEV1 in this
general adult population, but only in the absence of CRP
adjustment. The strengths of this study include its popula-
tion-based design, and the detailed characterization of the
participants which allowed us to investigate both, factors
associated with circulating AAT as well as the association
of the latter with lung function. Based on CRP measure-
ments we were able to exclude subjects with laboratory
evidence of inflammation at the time of the blood draw,
and to control for low-grade systemic inflammation as
potential confounder. These study advantages allowed us
to demonstrate the complexity of the interrelationship
between tobacco exposure, gender, circulating AAT and
CRP as well as lung function.
Positive associations between active smoking and AAT
levels have been reported before [18,19]. We additionally
considered ETS and smoking intensity and demonstrated
a positive dose-response relationship between tobacco
exposure and serum AAT, that was not confounded by
CRP. But this positive association between tobacco expo-
sure and circulating AAT did not consistently translate
into an inverse association between AAT and lung func-
tion in smokers. In fact we found a positive AAT/FEV1
association in men and postmenopausal women who
smoked heavily, in line with the interaction of smoking
and inherited AAT deficiency on COPD risk and lung
function [20]. Von Ehrenstein et al [6] found adverse
effects of ETS on lung function to be strongest in children
with low, CRP-adjusted AAT levels. The differences in
FEV1 that we observed were small from an individual per-
spective; yet even small differences in FEV1 at normal lev-
els are predictive of overall or cause-specific mortality and
may ultimately shift a substantial percentage of the gen-
eral population into the group of subjects with clinically
relevant lung function deficits [21].
Our results suggest that female hormones influence circu-
lating AAT levels and modify the AAT/lung function asso-
ciation. Gender differences in both, circulating AAT [20]
and respiratory health [22] are well established and may
reflect biological differences in the interrelations between
smoking, AAT and lung function. Gender differences in
AAT levels were even present in the situation of severe AAT
deficiency although the results were not adjusted for hor-
mone intake [23]. While previous reports on the associa-
tion between use of oral contraceptives and AAT in the
Table 7: Adjusted* mean AAT serum levels in women by menopausal status and hormone intake
Predictor Number of subjects AAT (SE) (g/L) no CRP 
adjustment
AAT (SE) (g/L) CRP 
adjustment
Menopausal status in women 
without hormonal treatment¶,†:
Premenopausal 806 1.277 (0.007) 1.282 (0.007)
Postmenopausal 848 1.256 (0.007) 1.252 (0.006)
p = 0.038 p = 0.003
Oral contraceptives in 
premenopausal women:
no OC use 640 1.278 (0.007) 1.288 (0.007)
use of OC 166 1.520 (0.016) 1.470 (0.016)
p < 0.001 p < 0.001
Hormone replacement in 
postmenopausal women:
no use of HRT 324 1.207 (0.015) 1.216 (0.014)
use of HRT 524 1.272 (0.015) 1.268 (0.014)
p < 0.001 p < 0.001
* adjusted for BMI, age, active and passive smoking, alcohol consumption, systolic blood pressure and study area ¶perimenopausal women (n = 82) 
and women with unclear/missing information on hormonal use (n = 243) were excluded; †not adjusted for age due to co-linearity between age and 
menopausal status; OC = oral contraception; HRT = hormone replacement therapy;Respiratory Research 2008, 9:35 http://respiratory-research.com/content/9/1/35
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blood exist [24,25], our study extends this association to
postmenopausal hormone intake. Our findings are com-
patible with an effect of estrogens or progesterone on
hepatic AAT metabolism, which may be mediated by an
inhibition of cytochrome P-450 activities [26].
The observed modification of the FEV1/AAT association
by smoking and hormonal factors as well as by CRP-
adjustment may reflect the dual role of AAT as a respira-
tory disease biomarker. The net impact of AAT on lung
function seems to be the result of context-dependent (i.e.
smoking, gender) and contrasting protective and inflam-
matory effects in the respiratory tract. On the one hand,
elevated serum AAT can reflect a beneficial shift of the pro-
tease-antiprotease balance, the centre piece of the patho-
physiological pathway mediating the effect of severe AAT
deficiency on COPD. On the other hand elevated serum
AAT can also reflect low-grade inflammatory processes in
the lung [27], a hypothesized COPD risk factor [9]. Con-
sistent with these findings, we could detect a positive rela-
tionship between AAT and CRP concentrations. Previous
studies observed inverse association between inflamma-
tion-sensitive proteins, including serum AAT, and pulmo-
nary function in population-based samples of adults
[7,8]. Subjects with CRP > 10 mg/l were not excluded, and
smoking was not investigated as a potential effect modi-
fier. Significantly higher AAT levels were even reported for
AAT deficient (PIZZ) patients with COPD compared to
PIZZ individuals without COPD thus further supporting
the hypothesis that AAT levels may also represent an
ongoing inflammatory process [28].
The observed inverse association observed between AAT
and BMI might also be reflecting different roles of AAT. In
general, positive association between CRP and BMI have
been observed among obese persons, an effect that was
attributed to low-grade systemic inflammation [29].
However, the acute phase response is a complex signalling
pathway and different acute phase proteins are distinctly
regulated and expressed [30]. Engström et al [31] found a
number of inflammation-sensitive proteins to be posi-
tively related to BMI, yet AAT levels were highest in
healthy men in the lowest BMI quartile.
The cross-sectional nature of the study prohibits assess-
ment of cause and effect as well as differentiation between
etiological and prognostic effects of variation in AAT con-
centrations. This aspect may be of relevance to considera-
tions about the pathophysiological mechanism
underlying the observed associations. Dahl et al[20]
found the AAT MZ genotype to be associated with lung
function among individuals with clinically established
COPD, but not among subjects without COPD in the gen-
eral population. A possible criticism to our paper is the
lack of information about potential AAT deficiency
pheno- or genotypes in the study population. But we spe-
cifically investigated the potential value of variation at the
serum AAT protein levels as a biomarker for lung function
impairment in the general population. Since the observed
associations were insensitive to the AAT cut-off level rare,
unrecognized AAT deficiency alleles are an unlikely source
of bias in this study. Another concern of the current cross-
sectional study, which is embedded into the SAPALDIA
cohort, is the potential for selection bias due to non-par-
ticipation. Never smokers were more likely to participate
at follow-up [11]. If serum AAT was associated with the
likelihood of participation at baseline or follow-up this
could have distorted results on associations between AAT
and other factors. Although unlikely, we cannot defini-
tively rule out such bias in the absence of AAT measure-
ments in non-participants.
Conclusion
Our cross-sectional results demonstrated that a complex
interrelationship among tobacco exposure, gender, circu-
lating AAT, lung function, and systemic inflammatory sta-
tus exists. If the observed interactions between these
variables are confirmed in larger and longitudinal studies,
the potential utility of circulating AAT as a biomarker for
susceptibility to respiratory disease seems limited. The
reported interactions are also relevant to studying the
impact of genetic variation in AAT on lung health.
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